Mutations leading to aberrant cytoplasmic localization of Nucleophosmin 1 (NPM1) have been recently identified as the most frequent genetic alteration in acute myelogenous leukemia. However, the oncogenic potential of this nucleophosmin mutant (NPMc +) has never been established, which casts doubt on its role in leukemogenesis. By performing classical transformation assays, we find that NPMc +, but not wild-type NPM, cooperates specifically with adenovirus E1A to transform primary mouse embryonic fibroblasts in soft agar. We demonstrate that NPMc + blocks the p19 Arf (Arf) induction elicited by E1A. Surprisingly, however, we find that NPMc + induces cellular senescence and that E1A is able to overcome this response. We propose a model whereby the NPMc + pro-senescence activity needs to be evaded for oncogenic transformation, even though NPMc + can concomitantly blunt the Arf/p53 pathway. These findings identify for the first time NPMc + as an oncogene and shed new unexpected light on its mechanism of action.
Introduction
Nucleophosmin (NPM) is a multifunctional nucleolar protein involved in many different cellular processes. These include ribosome biogenesis, stabilization of critical tumor suppressors p53 and p19 Arf , maintenance of genomic stability, DNA transcription and response to stress stimuli (Grisendi et al., 2006) . NPM1 is one of the most frequent targets of genetic alterations in hematopoietic tumors. It is translocated with a number of promiscuous partners in acute promyelocytic leukemia, anaplastic large cell lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia and myelodysplasia (Morris et al., 1994; Redner et al., 1996; Yoneda-Kato et al., 1996) . Moreover, it is mapped to a region of chromosome 5 that is deleted in therapy-related MDS and other types of cancers (Mendes-da-Silva et al., 2000; Olney and Le Beau, 2002) . We have recently shown that NPM can act as a tumor suppressor through the generation and characterization of an NPM hypomorphic series in vivo (Grisendi et al., 2005) .
Strikingly, NPM1 has also been found mutated in about 60% of primary adult AML with a normal karyotype (Falini et al., 2005) . These NPM mutants are aberrantly localized to the cytoplasm of leukemic blasts, and are hence termed NPM cytoplasmic positive (NPMc þ ). The cytoplasmic localization is caused by frameshift mutations in one allele of the NPM1 gene, encoding novel proteins with an additional nuclear export signal motif but without the normal nucleolar localization motif . Since NPMc þ retains the oligomerization domain of NPM, it can behave as a dominant-negative mutant sequestering the endogenous NPM to the cytoplasm . At the same time, this genetic event reduces the endogenous level of NPM to hemizygosity. It remains to be addressed whether any tumor-suppressive function of NPM is compromised and which novel oncogenic functions are gained by NPMc þ . Two recent reports show that exogenous overexpression of NPMc þ delocalizes and destabilizes p19
Arf , thus reducing the ability of Arf to initiate a p53 response and to induce cell cycle arrest in an Arf-inducible cell line (den Besten et al., 2005; Colombo et al., 2006) . However, to date there is no published evidence that NPMc þ can act as an oncogene and transform primary cells. On the contrary, it seems to exhibit an antiproliferative activity when overexpressed in NIH3T3 cells that do not express p19
Arf (den Besten et al., 2005) . Here we show that NPMc þ can indeed act as an oncogene when its pro-senescence activity is evaded.
Results
Testing the oncogenic potential of NPMc þ in primary mouse embryonic fibroblasts To determine the oncogenic potential of NPMc þ in vitro, we first generated retroviral constructs containing Flag-tagged NPMc þ , as well as the wild-type NPM as a control. We used these constructs to transduce earlypassage primary mouse embryonic fibroblasts (MEFs) and found, as expected, NPMc þ aberrantly localized to the cytoplasm (Figure 1a ), whereas exogenous NPM mainly localized to the nucleolus (Figure 1b) . In addition, endogenous Npm was partially delocalized to the cytoplasm in the NPMc þ -expressing MEFs (Figure 1a ). This is consistent with previous findings that NPMc þ binds to and sequesters endogenous NPM to the cytoplasm (Falini et al., 2005; Colombo et al., 2006) .
We next examined the ability of NPMc þ to promote oncogenic transformation by performing transformation assays in soft agar with NPMc þ -transformed primary MEFs. This assay is a measure of anchorageindependent growth, characteristic of tumor cells. It is known that primary MEFs require at least two cooperating oncogenes to become transformed (Land et al., 1983) . We thus tested whether coexpression of NPMc þ and another oncogenic event could promote the growth of primary MEFs in soft agar. We performed these experiments expressing wild-type NPM in parallel as a control since it has been shown that overexpression of NPM can transform NIH3T3 cells (Kondo et al., 1997) .
As expected, NPMc þ alone did not transform primary wild-type MEFs (Figure 2a ). Unlike the positive control H-Ras V12 , NPMc þ also failed to transform earlypassage Arf À/À and p53 À/À MEFs ( Figure 2b ). This is consistent with previous findings that NPMc þ failed to transform NIH3T3 cells that are Arf null (den Besten et al., 2005) . In addition, NPMc þ did not cooperate with oncogenic H-Ras V12 to transform primary MEFs, unlike the dominant-negative p53-positive control (Figure 2c ).
Since, in leukemic blasts, NPMc þ is frequently associated with internal tandem duplication (ITD) of the Fms-like tyrosine kinase (FLT3) gene, we tested the oncogenic cooperation between NPMc þ and FLT3-ITD in MEFs. We found that together they did not transform primary MEFs in soft agar either (Figure 2d) . We also noticed that the level of expression of NPMc þ was consistently less than NPM in all primary cells transduced with Flag-tagged retroviruses (see Figures 2 and 3a) . We found that the lower level of NPMc þ protein expression is not due to decreased transcription (Supplementary Figure 1) . This could suggest that NPMc þ has a shorter halflife, the cells cannot tolerate high levels of NPMc þ expression, or else NPMc þ mRNA is not translated as efficiently.
NPMc þ transforms primary MEF in cooperation with oncogenic E1A Interestingly, however, we found that NPMc þ cooperated with the E1A oncogene to transform primary MEFs ( Figure 3a and Supplementary Figure 2A) . E1A alone or in combination with wild-type NPM did not transform primary MEFs in soft agar, thus highlighting the novel oncogenic effect of the C-terminal mutant motif in NPMc þ . The transformed colonies coexpressing NPMc þ /E1A were slightly smaller than Ras v12 /E1A colonies, but were clearly visible by eye after 3 weeks of culture in soft agar. Unlike E1A-expressing cells, NPMc þ /E1A-transformed cells consistently showed high efficiency at forming foci in low-density seeding assays ( Figure 3b ) and high growth rate (Figure 3c) Figure  2B) and became non-adherent upon passaging; therefore, we never obtained a sufficient number of cells to perform focus-forming assays and growth curve. We did not observe a major difference between vector/ E1A, NPM/E1A and NPMc þ /E1A cells in terms of cell cycling ability after selection (Supplementary Figure 2C ).
NPMc þ rescues E1A-induced Arf/p53 activation E1A is an extensively studied adenoviral oncogene (Dyson and Harlow, 1992; Gallimore and Turnell, 2001) , and it has been used as a tool to dissect molecular pathways of cooperative oncogenic transformation. E1A contains four conserved regions, named CR1-4. E1A CR2 binds retinoblastoma (RB) family members, de-repressing E2F transcription factors and inducing cell cycle progression. However, E1A-expressing cells eventually degenerate in soft agar and do not form colonies (Ruley, 1983) . This is largely due to E1A's ability to induce p53 stabilization through upregulation of Arf (de Stanchina et al., 1998) , CBP/p300 binding (Grossman et al., 1998) and proteosome modification by E1A CR1 (Zhang et al., 2004) . The stabilization of p53 leads to programmed cell death unless blocked by another oncogene. Indeed, inhibition of apoptosis by E1B (Yew and Berk, 1992) or Ras (Lin et al., 1995) is required for E1A-induced cell transformation. It was shown that inactivation of Arf is a central mechanism for the attenuation of apoptosis in E1A-expressing cells (de Stanchina et al., 1998) . To explain why NPMc þ is required for E1A-driven transformation, we hypothesize that, since NPMc þ blocks Arf (den Besten et al., 2005; Colombo et al., 2006) , it may allow E1A to evade the p53-dependent cell cycle arrest and apoptosis. Indeed, we found that in the NPMc þ /E1A-transformed cells, unlike in the NPM/E1A cells, there was a significant decrease in p19
Arf response ( Figure 4a ). The p53 transcriptional activity was also reduced as seen by the lower levels of the p53 target gene p21 CIP ( Figure 4a ). This is consistent with recent findings that overexpression of NPMc þ in an Arf-inducible cell line causes delocalization of Arf to the cytoplasm, destabilization of Arf and a blunted Arf-induced activation of the p53 transcriptional program (den Besten et al., 2005; Colombo et al., 2006) . This suggests that NPMc þ rescues E1A-induced Arf and p53 activation.
We also looked at the p19 Arf level and localization in primary cells from our NPM hypomorphic series (Grisendi et al., 2005) . Interestingly, we found that Arf level was also dramatically reduced in NPM hy/hy MEFs expressing very little endogenous Npm (Figure 4b ). In addition, Arf was delocalized to the nucleus and the NPMc + is an oncogene K Cheng et al cytoplasm and no longer co-localized with the endogenous Npm (Figure 4c ). Since NPM is important for Arf stability, this result indicates that NPMc þ might regulate Arf either directly or indirectly through NPM inhibition.
E1A rescues NPMc þ -induced senescence
To understand why E1A is required for NPMc þ -driven transformation, we looked at the possible effects of NPMc þ expression that E1A could cooperate with. It is known that the 'immortalization' function of E1A counters the senescence that otherwise happens in primary MEFs after multiple cell cycles (Berk, 2005) . Interestingly, we found that both NPM and NPMc þ -induced growth arrest in early-passage primary MEFs (Figure 5a ). This growth arrest is accompanied by a twofold increase in cellular senescence as assayed by senescence associated-b-galactosidase activity (Figure 5b) . Interestingly, we found that the addition of E1A completely rescued NPMc þ -induced senescence, as with Ras-induced senescence (Figure 5b) . Surprisingly, we found that NPMc þ , MEFs (Figure 5c ). These data suggest that the senescence induced by NPMc þ is indeed Arf-independent, as NPMc þ was shown to block Arf response and p53 transcriptional activity (Figure 4a ).
It has been recently shown that oncogene-induced senescence is associated with signs of DNA replication stress (Di Micco et al., 2006) . Considering that wild-type NPM has a function in modulating chromosome condensation/decondensation and is recruited to sites of dsDNA breaks (Frehlick et al., 2007) , we hypothesized that NPMc þ may lead to senescence by blocking the NPM function in DNA damage response. However, at the passage where senescence and growth curve was analysed, overexpression of NPMc þ in wildtype MEFs was not accompanied by positivity for markers characteristically induced in cells suffering DNA damage as shown by the scarce nuclear staining NPMc + is an oncogene K Cheng et al of phospho-histone H2A.X (Ser139), unlike those of the UV-irradiated MEFs (Supplementary Figure 3A) . Additionally, Ser15 phosphorylation of p53, another DNA damage marker, was not induced in NPMc þ expressing MEFs (Supplementary Figure 3B) . We also found that NPMc þ overexpression is not associated with significant alterations in genomic instability and in centrosome numbers (Supplementary Figure 3C) . This is perhaps expected because the cytoplasmic localization of NPMc þ does not presumably interfere with its ability NPMc + is an oncogene K Cheng et al to associate with the centrosome and hence control proper centrosome duplication.
Discussion
Our data led us to propose a model of cooperative oncogenic transformation by NPMc þ and E1A ( Figure 6 ). Upon oncogenic stress by E1A, Arf accumulates in the nucleolus where NPM normally stabilizes it. However in combination with NPMc þ , Arf is destabilized and p53 activation is blocked. At the same time, E1A rescues NPMc þ -induced senescence. These reciprocal antagonistic signals eliminate the cellular fail-safe mechanisms induced by oncogenes, namely Arf/p53 activation and senescence, unleashing the oncogenic potential of E1A and NPMc þ . Since NPM is required for Arf stability (Colombo et al., 2005) , our data suggest two possibilities for the dominant-negative action of NPMc þ on Arf: NPMc þ delocalizes NPM to the cytoplasm, thus attenuating NPM's protective role on Arf (den Besten et al., 2005) , or NPMc þ directly delocalizes Arf to the cytoplasm and destabilizes it (Colombo et al., 2006) . Our data showed that the endogenous NPM was only partially delocalized by NPMc þ (Figure 1a) , therefore supporting the second hypothesis.
It is now widely acknowledged that ARF protects cells from oncogenic transformation. Sustained hyperproliferative signals conveyed by somatically activated oncogenes can induce ARF gene expression and trigger a p53 response that eliminates incipient cancer cells (Sherr, 2006) . Disruption of this tumor surveillance pathway predisposes cells to cancer. Inactivation of ARF and P53 by deletion, silencing or mutation has been frequently observed in many forms of human cancer. A notable exception is represented by the hematopoietic tumors, where genetic alterations of members of the ARF/P53 pathway are relatively rare (Krug et al., 2002) . In these tumors, functional inactivation of ARF might be selected. Although NPMc þ may very well possess novel oncogenic functions by itself, our study confirms that one oncogenic role of NPMc þ is to antagonize the tumor suppressor function of ARF. Furthermore, we propose that reactivation of the downstream targets of NPMc þ , such as ARF/P53 (for example, through the utilization of HDM2 inhibitors such as nutlins (Vassilev et al., 2004) ), and/or the potentiation of cellular senescence may represent an attractive therapeutic approach for the treatment of AMLs harboring NPMc þ .
The induction of premature senescence is typical of a number of oncogenes (Serrano et al., 1997; Bartkova et al., 2006) . Wild-type NPM was previously shown to induce senescence by stabilization of p53 (Colombo et al., 2002) . However, it is surprising that NPMc þ also induced senescence, as it was shown to block Arf and the p53 activity. In fact, we found that in primary MEFs expressing NPMc þ , Arf and p53 levels were not upregulated (data not shown). Indeed, senescenceassociated b-gal activity and growth arrest were detected even in early-passage Arf À/À MEFs expressing NPMc þ (Figure 5c ), suggesting that NPMc þ elicits an Arfindependent senescence response.
We are currently investigating the possibility that NPMc þ induces senescence through pRb, which is known to be sequestered and inactivated by E1A. In fact, one recent report showed that downregulation of intracellular NPM resulted in recruitment of pRb to the promoter resulting in transcriptional inhibition of E2F1 target genes (Lin et al., 2006) . This scenario may be mimicked if NPMc þ acts as a dominant-negative mutant sequestering NPM to the cytoplasm and interfering with its normal functions. Indeed, loss of RB function due to mutation and deletion is found in a significant number of acute myelogenous leukemia cases (Sauerbrey et al., 1998) .
Thus, we speculate that the reason why NPMc þ does not cooperate with Ras is because Ras may not be able to rescue NPMc þ -induced senescence while, in principle, NPMc þ could block Ras-induced senescence accompanied by ARF induction (Palmero et al., 1998) . Interestingly, NPMc þ inversely correlates with NRAS mutations in AML patients (Verhaak et al., 2005) . The observation that NPMc þ does not transform Arf À/À or p53 À/À MEFs is also in agreement with the notion that NPMc þ induces senescence through an Arf-independent mechanism.
Analysis in large AML clinical trials demonstrates that 40-45% of NPMc þ AML patients carry FLT3-ITD (Thiede et al., 2006) . Hence, our results showing the lack of cooperation between FLT3-ITD and NPMc þ in transforming MEFs should be cautioned, first because there are no known oncogenes that can cooperate with FLT3-ITD in soft agar transformation assay, and second because the cooperation might be tissue-specific and occurs only in the hematopoietic compartment. Our experiments carried out in MEFs NPMc + is an oncogene K Cheng et al may therefore not fully recapitulate the pathological condition in leukemic cells. In addition, the level of NPMc þ expression achieved in MEFs could not reflect those observed in the AML blasts. Therefore, additional approaches are required to examine fully the role of NPMc þ , such as knock-in strategy in vivo. However, it should be noticed that the levels of NPMc þ in our assays are lower than those of NPM, suggesting that we may be underestimating the biological effects of NPMc þ .
It is surprising that while wild-type NPM is thought to be oncogenic, as it transforms NIH3T3 cells when overexpressed and is upregulated in proliferating and cancer cells (Grisendi et al., 2006) , we did not find that overexpression of NPM cooperated with any of the oncogenic events tested here to transform primary MEFs (Figures 2 and 3a) . Primary cultured MEFs contain fewer mutations than immortalized cell lines such as NIH3T3. Hence, our NPM overexpression setting in stably infected primary cells is probably much more stringent in analysing cellular transformation than transient overexpression experiments done in cell lines. This therefore suggests that wild-type NPM may not be a very potent oncogene in primary cells.
In conclusion, we demonstrate for the first time that NPMc þ acts as an oncogene. We also show that it elicits an Arf-independent cellular senescence response that needs to be evaded for NPMc þ to exert its transforming potential. Collectively, our findings suggest that NPMc þ may be a causative event instead of a consequence of leukemia.
Materials and methods
Cell culture, transfections and viral transduction procedure Primary wild-type, p53 À/À and Arf À/À MEFs were prepared from E13.5 embryos. Transfections of the packaging cell line (Phoenix, Eco, ATCC, Manassas, VA, USA) were done using Lipofectamine Plus in Optimem (Gibco, Carlsbad, CA, USA) without serum or antibiotics. Early-passage wild-type and Arf À/À MEFs (P1-2) and p53 À/À MEFs (P5) were infected with empty vector pMSCVpuro-IRES-GFP (PIG), PIG-NPM, PIG-NPMc þ , pBabe-hygro-Ras V12 , pBabe-hygro-E1A, MSCVhygro-Flt3ITD, pBabe-puro-Ras V12 and pBabe-puro-p53DD retroviruses, separately or combined as indicated. Antibiotic selection was done for 2 days in 2 mg/ml puromycin or 4 days in 75 mg/ml hygromycin and in combination of the two. Cells were then harvested and passaged for 1-2 times in selection medium before seeding for transformation assay, focusforming assay, growth curve, senescence assay and immunofluorescence. Lysates for western blots were also prepared at the same time.
Plasmids and constructs
Human NPM (ATCC, IMAGE clone 4106023, Manassas, VA, USA) was PCR-amplified and cloned in-frame into the BamHI/EcoRI restriction sites of pCMV-Tag2B vector containing a Flag sequence (Stratagene, La Jolla, CA, USA). The flag-NPM were excised with NotI/EcoRV and cloned into the HpaI site of PIG retroviral vector. Site-directed mutagenesis was performed to obtain the most frequent mutation of NPMc þ (mutation A) from pCMV-Tag2B NPM. NPMc þ was amplified with BclI ends and cloned into the BglII site of PIG retroviral vector. All plasmids generated were sequenced. Retroviral vectors pBabe-hygro-Ras V12 , pBabe-hygro-E1A, pBabe-puro-Ras V12 were obtained from S Lowe and pBabepuro-p53DD (dominant-negative) was obtained from O Moshe. Flt3-ITD (provided by G Gilliland) was cloned into the HapI site of pMSCVhygro retroviral vector (Clontech, Mountain View, CA, USA).
Soft agar transformation assay and focus-forming assay Transformation assays were performed by re-suspending 5 Â 10 4 cells in complete Dulbecco's modified Eagle's medium (2 Â ) containing 0.3% agarose and seeding (in triplicate) into 35-mm plates containing a 3-ml layer of solidified 0.6% agar in complete medium. Foci were scored 3 weeks later from duplicate wells. Focus-forming assays were performed in triplicate by plating a total of 2000 cells per well in 12-well plates (in triplicate) and culturing for 10-12 days before staining with crystal violet. Each transformation assay or focus-forming assay was repeated at least twice, and representative experiments are shown in figures.
Proliferation assays
Growth curves were generated by seeding 2.5 Â 10 4 cells per well in 12-well plates, each clone in triplicate. Plates were fixed on days 0, 2, 4 and 6. Fixed plates were stained with crystal violet, extracted with 10% acetic acid and the relative cell number was measured by absorbance at 595 nm.
Western blot and immunofluorescence
For western blot analysis, the following antibodies were used: Flag (2368, Cell Signaling, Danvers, MA, USA), E1A (Ab-1, Neomarkers, Fremont, CA, USA), Pan Ras (Ab-3, Oncogene, San Diego, CA, USA), p19
Arf (Ab-1, Neomarkers), p53 (CM5, Novocastra, Balliol Business Park West, Benton Lane, UK), phospho-p53 (Ser15) (9284, Cell Signaling) and p21 (F5, Santa Cruz Biotechnology, Santa Cruz, CA, USA). For immunofluorescence, cells grown on coverslips were fixed in 10% formaldehyde. The antibodies used for immunofluorescence microscopy were anti-mouse NPM (B 0556), anti-rabbit p19 Arf (Ab-1, Oncogene), anti-rabbit NPMc þ (provided by B Falini, 1:100) and anti-rabbit phospho-histone H2A.X (Ser139) (2577, Cell Signaling). For detection, cells were incubated with FITCconjugated and/or Cy5-conjugated anti-mouse and antirabbit secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA). DNA was stained with 4 0 ,6-diamidino-2-phenylindole (DAPI).
Senescence assay
For the analysis of senescent cells, an equal number of cells (1 Â 10 4 ) were seeded in triplicate in each well of six-well plates. After 4 days, staining for the senescence marker b-Gal activity (X-Gal) was performed according to the manufacturer's protocol (Senescence Detection Kit, Oncogene Research Products) and the images taken at the same time.
